Deals Of The Week: Ironwood/Protagonist, Merck Serono/Domain, Pfizer/Theraclone
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
Genentech has come out fighting on multiple fronts in its attempt to retain Avastin’s breast cancer indication, proposing a new confirmatory study, submitting new Phase IV data and attacking FDA’s interpretation of both the underlying scientific data and its regulations on withdrawal.
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.